Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
  1. Home
  2. Search

Refine search

Refine search

Access:
Content type:
Publication date:
Apply   From and To filters
Subject: Show more
Journals Show more
Publishers: Show more
Societies Show more
Series: Show more
Collections: Show more

Actions for selected content:

Select all | Deselect all
  • View selected items
  • Export citations
  • Download PDF (zip)
  • Save to Kindle
  • Save to Dropbox
  • Save to Google Drive

Save Search

You can save your searches here and later view and run them again in "My saved searches".

Please provide a title, maximum of 40 characters.
Cancel
×

1 results

  • 22 - Future fertility insurance

  • from SECTION 5 - FUTURE FERTILITY INSURANCE: SCREENING, CRYOPRESERVATION OR EGG DONORS?
  • Edited by Susan Bewley, William Ledger, University of New South Wales, Sydney, Dimitrios Nikolaou
  • Book:
    Reproductive Ageing
    Published online:
    05 February 2014
    Print publication:
    01 June 2009, pp 237-242

  • Summary

    This chapter presents a discussion between an number of experts on fertility. Each person presents his/her views on future fertility insurance. According to Herman Tournaye, vitrification will completely change the clinical approach that is present today. On the other hand Helen Picton says that even with vitrification, we have to have good eggs to vitrify. If we can get the quality of the egg right, vitrification of metaphase II (MII)'s is what we will see being used in clinical practice, and successfully. Roger Gosden feels that embryo freezing should be offered where possible. There is need to raise awareness of the possibility of 'early ovarian ageing'. When discussing screening for early ovarian ageing, and fertility insurance, the question is whether any of these tests could be transferred from the field of assisted reproduction to the general population to be used in asymptomatic young women to predict their future fertility.